A genetic patch stops the devastating Dravet syndrome, with epileptic seizures that may be triggered by seeing geometric patterns | Science | EUROtoday

A revolutionary drawn Genetics has managed to cease seizures in youngsters and adolescents with Dravet syndrome, a uncommon type of intractable epilepsy, whose assaults could be triggered by infections, environmental warmth and even visible stimuli, similar to considering geometric patterns: stripes, squares or rhombuses. Spanish neurologist Antonio Gil-Nagel says that considered one of his sufferers, a four-year-old boy with 20 epileptic seizures a month, was one of many first to do that experimental therapy, developed by Uruguayan biologist Isabel Aznárez and her colleagues from the American firm Stoke Therapeutics. “The improvement was immediate, from the first injection. If things are as they seem, it is impressive,” says Gil-Nagel, from the Ruber International Hospital, in Madrid.

The youngster, handled in 2023, went from 20 assaults a month to only one disaster annually, remembers the neurologist. Gil-Nagel’s affected person acquired the remedy at London’s Great Ormond Street Children’s Hospital, which has been partially funded by copyrights of the character Peter Pan since 1929, when Scottish novelist James Matthew Barrie donated them to the establishment. The promising outcomes of that first scientific trial, carried out within the United States and the United Kingdom, have been printed this Wednesday within the specialised journal The New England Journal of Medicine. “It is the first genetic regulation treatment for epilepsy,” celebrates Gil-Nagel.

One in each 16,000 newborns has Dravet syndrome. In most instances, the origin is a mutation of the SCN1A gene, which alters the conduct of neurons and causes fixed epileptic seizures. Mortality reaches 15%. The experimental therapy, injected into the cerebrospinal fluid by means of a lumbar puncture, known as zorevunersen and is a genetic patch that reduces the results of the mutation.

81 youngsters and adolescents between 2 and 18 years outdated participated within the scientific trial. The experiment was designed to check the protection of the therapy, however scientists have additionally noticed that epileptic seizures have been decreased by 85% in three months in sufferers who acquired excessive doses. The advantages have been maintained throughout 20 months of follow-up, with reductions of between 60% and 90%. In addition, by combating the origin of the issue, the experimental remedy additionally achieves advantages in different points of the syndrome, similar to extreme cognitive and motor delays.

Researchers at Lurie Children’s Hospital in Chicago (USA), led by neurologist Linda Laux, have shared the case of Owen, a 12-year-old affected person with uncontrolled seizures, mental incapacity and strolling difficulties. The kid’s personal mom, named Austin, has detailed in an announcement that, after receiving the experimental therapy, her son speaks extra simply. “Now he can make friends. His quality of life has increased substantially,” the mom celebrated.

The opposed results recorded are gentle or average. The most annoying is a rise in protein ranges within the cerebrospinal fluid in nearly half of the instances, however with out detecting elevated intracranial strain or hydrocephalus. The firm Stoke Therapeutics, with greater than 200 million euros at first of 2025, goes to finance a brand new scientific trial, by which no less than two personal facilities in Spain will take part: the Hospital Ruber Internacional and the Clínica Universidad de Navarra. The American multinational Biogen has paid greater than 140 million euros to acquire the advertising rights for zorevunersen outdoors the United States, Mexico and Canada, though extra trials are nonetheless wanted to show that the therapy is efficient and secure.

Paradigm shift

Pediatrician Rocío Sánchez-Carpintero will direct the trials on the Clínica Universidad de Navarra. The researcher emphasizes that, till now, there have been solely therapies to alleviate the signs. “This is a paradigm shift. We went from treating one of the manifestations, epileptic seizures, to treating the disease. It is as if you use an antibiotic to kill the bacteria that causes pneumonia and, then, you no longer have a cough. Until now we were treating only the cough. Epilepsy is a manifestation of Dravet syndrome, it is not its cause,” explains Sánchez-Carpintero. “It is a historic milestone,” he applauds.

“The quality of life of patients today is horrible. Horrible. They have epileptic seizures that are not controlled with any drug, an intellectual disability that becomes increasingly evident, problems walking when they are adolescents, some symptoms similar to autism… Families practically live to be able to take care of them,” explains the pediatrician. “As there is a probability of sudden death associated with epilepsy, many parents take turns at night to, if there is a crisis, try to wake up their child so that he does not die. It is very difficult to live like this,” says Sánchez-Carpintero.

These kinds of genetic band-aids are known as antisense oligonucleotides. The first related therapy, licensed in 2016, was nusinersen, indicated for spinal muscular atrophy. It appeared with a value of $750,000 within the first 12 months and $375,000 in subsequent years, for every affected person. The outcomes of the subsequent scientific trial, anticipated in late 2028, will inform whether or not zorevunersen is certainly a possible therapy for devastating Dravet syndrome. “The outlook is very hopeful. I am very excited,” says the pediatrician.